Evidence map›Paper›PMID 23215766›Full record

ReviewInternational reviews of immunology2012

HIV-1 Nef in macrophage-mediated disease pathogenesis.

Susanna L Lamers, Gary B Fogel, Elyse J Singer, Marco Salemi, David J Nolan, Leanne C Huysentruyt, Michael S McGrath

Open access · greenAbstract readReview
In one paragraph

Review in International reviews of immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. HIV-1 subtypes maintain distinctive physicochemical signatures in Nef domains associated with immunoregulation.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2023
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Human Immunodeficiency Virus Infection and Host Defense in the Lungs.Seminars in respiratory and critical care medicine · 2016
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Susanna L LamersBioInfoExperts, Thibodaux, LA, USA.
Gary B Fogel
Elyse J Singer
Marco Salemi
David J Nolan
Leanne C Huysentruyt
Michael S McGrath
University of California, San Francisco · USUniversity of Florida · USNatural Selection (United States) · USUniversity of California, Los Angeles · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
NATIONAL NEUROLOGICAL AIDS BANKU24MH100929 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SINGER, ELYSE J · 2013 to 2023
$12.5M
National Neurological AIDS Bank (NNAB)R24NS038841 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SINGER, ELYSE J · 1998 to 2007
$12.0M
PBI Manufacture CoreU19MH081835 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HADLOCK, KENNETH · 2007 to 2011
$8.9M
National Neurological AIDS BankU01MH083500 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SINGER, ELYSE J · 2008 to 2012
$7.2M
Viral evolution in peropheral macrophages and brain during progression to AIDSR01NS063897 · NINDS · UNIVERSITY OF FLORIDA · PI SALEMI, MARCO · 2009 to 2021
$7.0M
National NeuroAIDS Tissue Consortium Statistics and Data Coordinating CenterU01MH083545 · NIMH · INDIANA UNIVERSITY INDIANAPOLIS · PI YIANNOUTSOS, CONSTANTIN THEODORE · 2008 to 2012
$3.3M
Role of HIV-1 Env Diversity in Cellular TropismR01AI065265 · NIAID · UNIVERSITY OF FLORIDA · PI GOODENOW, MAUREEN M · 2005 to 2009
$2.1M
NIAID NIH HHS AI065265NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI065265NIMH NIH HHS U01 MH083500NIMH NIH HHS U01MH083500NIMH NIH HHS U01 MH083545NIMH NIH HHS U19 MH081835NIMH NIH HHS U19MH081835;NIMH NIH HHS U24 MH100929NINDS NIH HHS R01 NS063897NINDS NIH HHS R01 NS063897-01A2NINDS NIH HHS R24 NS038841NINDS NIH HHS R24 NS-38841
6 · The paper itself

Abstract

Combined anti-retroviral therapy (cART) has significantly reduced the number of AIDS-associated illnesses and changed the course of HIV-1 disease in developed countries. Despite the ability of cART to maintain high CD4+ T-cell counts, a number of macrophage-mediated diseases can still occur in HIV-infected subjects. These diseases include lymphoma, metabolic diseases, and HIV-associated neurological disorders. Within macrophages, the HIV-1 regulatory protein "Nef" can modulate surface receptors, interact with signaling pathways, and promote specific environments that contribute to each of these pathologies. Moreover, genetic variation in Nef may also guide the macrophage response. Herein, we review findings relating to the Nef-macrophage interaction and how this relationship contributes to disease pathogenesis.

Indexed as

AnimalsDisease ProgressionHIV-1HIV InfectionsHost-Pathogen InteractionsHumansMacrophagesMutationnef Gene Products, Human Immunodeficiency VirusPolymorphism, GeneticSignal TransductionVirus Replicationnef Gene Products, Human Immunodeficiency Virusnef protein, Human immunodeficiency virus 1

Identifiers

PMID23215766
PMCPMC3544535
OpenAlexW2048837095

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.